Refractory Hematologic Malignancy: Clinical Trials

1 trial for Refractory Hematologic Malignancy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Recruiting 1
Phase 21Recruiting 1

Follow Refractory Hematologic Malignancy: new trials by email Literature Review of Refractory Hematologic Malignancy trials Research Report on Refractory Hematologic Malignancy

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Emavusertib, Ibrutinib - Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
Phase 1 / Phase 2RecruitingCuris, Inc.1522017-12-282026-10-06

Narrower conditions

Hematologic Neoplasms (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoproliferative Disorders (1)  ·  Neoplasms (1)  ·  Recurrence (1)

Broader conditions

Disease Attributes (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms by Site (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

CA-4948 (1)  ·  ibrutinib (1)

Sponsors

Curis, Inc. (1)

Countries

Czechia (1)  ·  France (1)  ·  Israel (1)  ·  Italy (1)  ·  Poland (1)  ·  Spain (1)  ·  United States (1)